Elizabeth D. Ferucci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elizabeth D. Ferucci has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
Peter Holck
P. Holck, PhD, MPH, Research Services Department, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA
10 shared publicationsTammy L. Choromanski
T.L. Choromanski, MPH, Research Services Department, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA
10 shared publications- Caroline Gordon
Rheumatology Research Group, Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, UK
5 shared publications Amy Wilson
A. Wilson, PhD, RN, Research Services Department, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA
4 shared publicationsFlora Lee
F. Lee, RN, Research Services Department, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA
4 shared publicationsHilary Parton
New York City Department of Health and Mental Hygiene Long Island City New York
4 shared publications
Latest Publications
- 13 September 2026
- Published by Wiley in Arthritis & Rheumatology
Age‐Specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta‐Analysis of Data From the Centers for Disease Control and Prevention Lupus Registries
Objective: Epidemiologic estimates for age at systemic lupus erythematosus (SLE) diagnosis are limited, particularly for men and racial and ethnic subpopulations in the United States. Leveraging the Centers for Disease Control and Prevention (CDC) National Lupus Registry network of population‐based SLE registries, meta‐analyses were performed estimating age‐specific incidence of SLE by sex, race, and ethnicity. Methods: The CDC network of SLE registries includes five state‐based registries, plus a sixth Indian Health Service registry. Incidence periods spanned calendar years 2002 to 2018. Registries provided age‐specific incidence of SLE, fulfilling the American College of Rheumatology SLE classification criteria, per 100,000 person‐years, stratified by sex, race, and ethnicity for the meta‐analyses. Results: Incidence rates among women were highest for those aged 30 to 39 years (12.7, 95% confidence interval [CI] 9.5–16.8), whereas rates among men were highest for those aged 60 to 69 years (2.1, 95% CI 1.3–3.4). Black women aged 20 to 39 years had the highest SLE incidence rates (23.6, 95% CI 20.7–26.8). Among women diagnosed with SLE before age 20 years, incidence was highest among Asian individuals (6.5, 95% CI 2.8–15.2). Among women diagnosed with SLE after age 60 years, incidence was highest among American Indian/Alaska Native individuals (9.4, 95% CI 3.4–15.4). Weighted percentages show 10.0% of those with SLE were diagnosed before age 20 years, whereas 15.1% were diagnosed after age 60 years. The largest proportion of individuals with SLE (22.1%) was diagnosed between ages 30 and 39 years. Conclusion: This study provides comprehensive sex‐ and race‐specific estimates of age at SLE diagnosis. The substantial later‐in‐life SLE incidence among men and disease burden in pediatric and older populations should raise awareness in considering SLE in the differential diagnosis in previously underrecognized groups. image
- 13 September 2026
- Published by Wiley in Arthritis & Rheumatology
Age‐Specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta‐Analysis of Data From the Centers for Disease Control and Prevention Lupus Registries
Objective: Epidemiologic estimates for age at systemic lupus erythematosus (SLE) diagnosis are limited, particularly for men and racial and ethnic subpopulations in the United States. Leveraging the Centers for Disease Control and Prevention (CDC) National Lupus Registry network of population‐based SLE registries, meta‐analyses were performed estimating age‐specific incidence of SLE by sex, race, and ethnicity. Methods: The CDC network of SLE registries includes five state‐based registries, plus a sixth Indian Health Service registry. Incidence periods spanned calendar years 2002 to 2018. Registries provided age‐specific incidence of SLE, fulfilling the American College of Rheumatology SLE classification criteria, per 100,000 person‐years, stratified by sex, race, and ethnicity for the meta‐analyses. Results: Incidence rates among women were highest for those aged 30 to 39 years (12.7, 95% confidence interval [CI] 9.5–16.8), whereas rates among men were highest for those aged 60 to 69 years (2.1, 95% CI 1.3–3.4). Black women aged 20 to 39 years had the highest SLE incidence rates (23.6, 95% CI 20.7–26.8). Among women diagnosed with SLE before age 20 years, incidence was highest among Asian individuals (6.5, 95% CI 2.8–15.2). Among women diagnosed with SLE after age 60 years, incidence was highest among American Indian/Alaska Native individuals (9.4, 95% CI 3.4–15.4). Weighted percentages show 10.0% of those with SLE were diagnosed before age 20 years, whereas 15.1% were diagnosed after age 60 years. The largest proportion of individuals with SLE (22.1%) was diagnosed between ages 30 and 39 years. Conclusion: This study provides comprehensive sex‐ and race‐specific estimates of age at SLE diagnosis. The substantial later‐in‐life SLE incidence among men and disease burden in pediatric and older populations should raise awareness in considering SLE in the differential diagnosis in previously underrecognized groups. image
- 15 April 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (10) , 1083-1089
Prevalence of Spondyloarthritis in Alaska Native and American Indian peoples of Alaska
Objective: The objective of this study was to determine the prevalence and clinical characteristics of spondyloarthritis in Alaska Native and American Indian (AN/AI) peoples of Alaska. Methods: We queried electronic health records from participating tribal health organizations within the Alaska Tribal Health System from 2012 to 2019 to identify adults with a potential diagnosis of spondyloarthritis based on ICD-9 or ICD-10 codes. Medical records were abstracted to confirm the diagnosis and clinical characteristics. Adults who were alive at the end of the study period and had a confirmed clinician diagnosis of spondyloarthritis were included in prevalence calculations. We determined whether included adults had medical record documentation of meeting spondyloarthritis classification criteria. Results: The age-adjusted prevalence of any form of spondyloarthritis was 355 per 100,000 adults (95% confidence interval (CI) 317-397); for psoriatic arthritis it was 162 (95% CI 137-191) and for ankylosing spondylitis it was 107 (95% CI 86-131). Two-thirds (67.0%) of adults with any form of spondyloarthritis who were tested were HLA B27 positive. Two-thirds of adults with spondyloarthritis other than psoriatic arthritis (69.1%) had documentation in their medical record to confirm that they met clinical classification criteria for axial spondyloarthritis. Conclusion: The prevalence of spondyloarthritis in AN/AI peoples of Alaska is lower than previously reported in this population but higher than most populations previously studied Understanding the increased prevalence of spondyloarthritis in this population may help clinicians identify and treat the condition in AN/AI peoples.
- 15 April 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (10) , 1083-1089
Prevalence of Spondyloarthritis in Alaska Native and American Indian peoples of Alaska
Objective: The objective of this study was to determine the prevalence and clinical characteristics of spondyloarthritis in Alaska Native and American Indian (AN/AI) peoples of Alaska. Methods: We queried electronic health records from participating tribal health organizations within the Alaska Tribal Health System from 2012 to 2019 to identify adults with a potential diagnosis of spondyloarthritis based on ICD-9 or ICD-10 codes. Medical records were abstracted to confirm the diagnosis and clinical characteristics. Adults who were alive at the end of the study period and had a confirmed clinician diagnosis of spondyloarthritis were included in prevalence calculations. We determined whether included adults had medical record documentation of meeting spondyloarthritis classification criteria. Results: The age-adjusted prevalence of any form of spondyloarthritis was 355 per 100,000 adults (95% confidence interval (CI) 317-397); for psoriatic arthritis it was 162 (95% CI 137-191) and for ankylosing spondylitis it was 107 (95% CI 86-131). Two-thirds (67.0%) of adults with any form of spondyloarthritis who were tested were HLA B27 positive. Two-thirds of adults with spondyloarthritis other than psoriatic arthritis (69.1%) had documentation in their medical record to confirm that they met clinical classification criteria for axial spondyloarthritis. Conclusion: The prevalence of spondyloarthritis in AN/AI peoples of Alaska is lower than previously reported in this population but higher than most populations previously studied Understanding the increased prevalence of spondyloarthritis in this population may help clinicians identify and treat the condition in AN/AI peoples.
- Open Access
- 11 January 2026
- Published by Wiley in ACR Open Rheumatology
- Vol. 8 (1) , e70140
Prevalence and Clinical Characteristics of Systemic Sclerosis in Alaska Native and American Indian Peoples in Alaska
Objective: Systemic sclerosis (SSc) is known to exhibit significant epidemiologic and clinical variation. This study aimed to describe the clinical and epidemiologic characteristics of SSc in Alaska Native and American Indian (AN/AI) individuals in Alaska. Methods: Adults with a potential diagnosis of SSc were identified through an electronic health record query for SSc‐related codes from 2012 to 2019 in the participating tribal health organizations in the Alaska Tribal Health System (ATHS). Detailed medical record abstraction was performed to confirm diagnoses and clinical characteristics, including demographics, SSc subtype, organ involvement, serologic test results, and medications. The denominator for prevalence was the 2019 ATHS user population aged ≥18 years. Results: The age‐adjusted prevalence of SSc was 354 (95% confidence interval [CI] 241–504) per 1,000,000 adults overall, 503 (95% CI 323–752) per 1,000,000 in women, and 188 (95% CI 82–379) per 1,000,000 in men. Of the 36 adults identified with SSc, the mean age at diagnosis was 59.9 years (median 62 years), with a female predominance (28 [77.8%]; female‐to‐male ratio 3.5:1). Diffuse SSc prevalence was 95 (95% CI 44–184), and limited SSc prevalence was 258 (95% CI 164–391) per 1,000,000. Although most clinical features appear to be similar to other populations, a high prevalence of pulmonary arterial hypertension, gastrointestinal manifestations, and telangiectasias were notable. Conclusion: This is the first study to describe the epidemiology and clinical characteristics of SSc in AN/AI individuals in Alaska. The prevalence, average age at onset, female predominance, and most clinical features are generally similar to those in studies of SSc in other populations.
- 11 January 2026
- Published by Wiley in ACR Open Rheumatology
- Vol. 8 (1) , e70140
Open AccessPrevalence and Clinical Characteristics of Systemic Sclerosis in Alaska Native and American Indian Peoples in Alaska
Objective: Systemic sclerosis (SSc) is known to exhibit significant epidemiologic and clinical variation. This study aimed to describe the clinical and epidemiologic characteristics of SSc in Alaska Native and American Indian (AN/AI) individuals in Alaska. Methods: Adults with a potential diagnosis of SSc were identified through an electronic health record query for SSc‐related codes from 2012 to 2019 in the participating tribal health organizations in the Alaska Tribal Health System (ATHS). Detailed medical record abstraction was performed to confirm diagnoses and clinical characteristics, including demographics, SSc subtype, organ involvement, serologic test results, and medications. The denominator for prevalence was the 2019 ATHS user population aged ≥18 years. Results: The age‐adjusted prevalence of SSc was 354 (95% confidence interval [CI] 241–504) per 1,000,000 adults overall, 503 (95% CI 323–752) per 1,000,000 in women, and 188 (95% CI 82–379) per 1,000,000 in men. Of the 36 adults identified with SSc, the mean age at diagnosis was 59.9 years (median 62 years), with a female predominance (28 [77.8%]; female‐to‐male ratio 3.5:1). Diffuse SSc prevalence was 95 (95% CI 44–184), and limited SSc prevalence was 258 (95% CI 164–391) per 1,000,000. Although most clinical features appear to be similar to other populations, a high prevalence of pulmonary arterial hypertension, gastrointestinal manifestations, and telangiectasias were notable. Conclusion: This is the first study to describe the epidemiology and clinical characteristics of SSc in AN/AI individuals in Alaska. The prevalence, average age at onset, female predominance, and most clinical features are generally similar to those in studies of SSc in other populations.
- 19 December 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (5) , 683-687
Building Consensus on the Essential Elements of the Musculoskeletal Physical Examination During Rheumatology Telehealth Encounters
Objective: Patients and providers encounter challenges when conducting virtual musculoskeletal physical examinations (PEs) during rheumatology telehealth encounters. Guidance for a structured virtual PE could enhance the quality of clinical information gleaned and management decisions made during rheumatology telehealth visits. This study aims to build expert consensus and identify the most essential elements as the first step in defining the virtual rheumatology musculoskeletal PE. Methods: A team with expertise in rheumatology telehealth, consisting of rheumatology attending physicians, educators, and a patient with rheumatic disease, conducted a modified Delphi to achieve consensus on the items determined to be most essential to the virtual rheumatology musculoskeletal PE. The modified Delphi consisted of two online surveys and a virtual meeting. Results: The team identified seven items essential to the rheumatology musculoskeletal telehealth PE. These items describe elements in a focused joint examination as well as the assessment for level of activity of inflammatory arthritis. The modified Delphi method excluded maneuvers related to assessment of muscle strength and widespread pain syndromes, determining that these elements were better conducted in person. Conclusion: A list of PE items most essential to rheumatology musculoskeletal telehealth encounters, supported by expert opinion and established evidence, marks the first step toward standardizing, evaluating, and teaching the virtual rheumatology PE. These items, alongside anticipated future revisions and improvements, promise to enhance the quality of telehealth care delivered to people with rheumatic diseases.
- 19 December 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 78 (5) , 683-687
Building Consensus on the Essential Elements of the Musculoskeletal Physical Examination During Rheumatology Telehealth Encounters
Objective: Patients and providers encounter challenges when conducting virtual musculoskeletal physical examinations (PEs) during rheumatology telehealth encounters. Guidance for a structured virtual PE could enhance the quality of clinical information gleaned and management decisions made during rheumatology telehealth visits. This study aims to build expert consensus and identify the most essential elements as the first step in defining the virtual rheumatology musculoskeletal PE. Methods: A team with expertise in rheumatology telehealth, consisting of rheumatology attending physicians, educators, and a patient with rheumatic disease, conducted a modified Delphi to achieve consensus on the items determined to be most essential to the virtual rheumatology musculoskeletal PE. The modified Delphi consisted of two online surveys and a virtual meeting. Results: The team identified seven items essential to the rheumatology musculoskeletal telehealth PE. These items describe elements in a focused joint examination as well as the assessment for level of activity of inflammatory arthritis. The modified Delphi method excluded maneuvers related to assessment of muscle strength and widespread pain syndromes, determining that these elements were better conducted in person. Conclusion: A list of PE items most essential to rheumatology musculoskeletal telehealth encounters, supported by expert opinion and established evidence, marks the first step toward standardizing, evaluating, and teaching the virtual rheumatology PE. These items, alongside anticipated future revisions and improvements, promise to enhance the quality of telehealth care delivered to people with rheumatic diseases.
- Open Access
- 15 November 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (12) , 1459-1465
Prevalence and Incidence of Sjögren's Disease in Alaska Native and American Indian Peoples of Alaska
Objective: Our objective was to determine the prevalence, incidence, and clinical characteristics of Sjögren's disease (SjD) in Alaska Native and American Indian (AN/AI) peoples of Alaska. Methods: We identified adults with SjD by querying electronic health records from participating tribal health organizations within the Alaska Tribal Health System (ATHS). Medical records were abstracted for adults with diagnostic codes for SjD. Individuals were included if they were diagnosed with SjD by a rheumatologist. Prevalence and incidence were calculated using the ATHS user population in 2019 (point prevalence) and from 2012 to 2019 (incidence), with direct age adjustment to the 2000 standard US population. We evaluated whether adults met modified criteria (positive Ro/SSA antigen with sicca symptoms), 2016 American College of Rheumatology (ACR)/EULAR, and 2012 ACR criteria. Results: The age‐adjusted prevalence of SjD was 199 per 100,000 adults (95% confidence interval [CI] 170–231); for primary SjD, it was 129 (106, 155), and for secondary SjD, it was 70 (95% CI 54–91). The age‐adjusted incidence over the period was 16.6 (95% CI 13.7–20.0) per 100,000 person‐years. Two‐thirds (66%) of adults met modified criteria. Only 5% had a salivary gland biopsy performed, and only 3% met the 2016 ACR/EULAR or 2012 ACR criteria. The most common associated conditions in secondary SjD were rheumatoid arthritis and systemic lupus erythematosus. Conclusion: The prevalence and incidence of SjD in AN/AI peoples is higher than other populations. These results may help clinicians to identify and treat this condition. image
- 15 November 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (12) , 1459-1465
Open AccessPrevalence and Incidence of Sjögren's Disease in Alaska Native and American Indian Peoples of Alaska
Objective: Our objective was to determine the prevalence, incidence, and clinical characteristics of Sjögren's disease (SjD) in Alaska Native and American Indian (AN/AI) peoples of Alaska. Methods: We identified adults with SjD by querying electronic health records from participating tribal health organizations within the Alaska Tribal Health System (ATHS). Medical records were abstracted for adults with diagnostic codes for SjD. Individuals were included if they were diagnosed with SjD by a rheumatologist. Prevalence and incidence were calculated using the ATHS user population in 2019 (point prevalence) and from 2012 to 2019 (incidence), with direct age adjustment to the 2000 standard US population. We evaluated whether adults met modified criteria (positive Ro/SSA antigen with sicca symptoms), 2016 American College of Rheumatology (ACR)/EULAR, and 2012 ACR criteria. Results: The age‐adjusted prevalence of SjD was 199 per 100,000 adults (95% confidence interval [CI] 170–231); for primary SjD, it was 129 (106, 155), and for secondary SjD, it was 70 (95% CI 54–91). The age‐adjusted incidence over the period was 16.6 (95% CI 13.7–20.0) per 100,000 person‐years. Two‐thirds (66%) of adults met modified criteria. Only 5% had a salivary gland biopsy performed, and only 3% met the 2016 ACR/EULAR or 2012 ACR criteria. The most common associated conditions in secondary SjD were rheumatoid arthritis and systemic lupus erythematosus. Conclusion: The prevalence and incidence of SjD in AN/AI peoples is higher than other populations. These results may help clinicians to identify and treat this condition. image
- 27 May 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (10) , 1246-1253
Development, Usability, and Validity Evidence of a Rheumatology Telehealth Feedback Form
Objective: Rheumatology telehealth is widespread, making it essential that rheumatology fellows‐in‐training (FITs) achieve competence delivering telehealth care before entering the workforce. Feedback enhances telehealth skill development. This study develops a Rheumatology Telehealth Feedback Form (RTFF) that incorporates existing data and expertise as well as gathers validity evidence supporting its use.Methods: The American College of Rheumatology Workforce Solutions Committee formed a working group with expertise in rheumatic diseases, telehealth, and medical education. The working group conducted a modified Delphi and focus groups to define content grounded in Rheumatology Telehealth Competencies and evidence‐based practice as well as develop the RTFF. Rheumatology educators and FITs piloted the RTFF during patient care and simulated telehealth encounters, rating the helpfulness of the RTFF and providing data to calculate intraclass correlation coefficients (ICCs).Results: The modified Delphi identified 16 skills essential to conducting rheumatology telehealth encounters, which were converted into 17 items on the RTFF. Comment boxes prompted supplementary narrative. Five educators and 10 FITs piloted the materials. All educators (5 of 5) “agreed” or “strongly agreed” that the RTFF helped teach rheumatology telehealth skills. ICCs calculated from two simulated telehealth encounters demonstrated moderately to strongly supportive interrater reliability (ICC = 0.857 and 0.632, respectively).Conclusion: The RTFF incorporates an evidence‐based, expert consensus of the skills most essential for rheumatology telehealth encounters. Educators can use the RTFF as a guide for observing FITs delivering telehealth care, providing formative feedback, and helping FITs develop their skills before entering the workforce. The RTFF is the first direct observation formative assessment tool designed for teaching rheumatology telehealth skills. image
- 27 May 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (10) , 1246-1253
Development, Usability, and Validity Evidence of a Rheumatology Telehealth Feedback Form
Objective: Rheumatology telehealth is widespread, making it essential that rheumatology fellows‐in‐training (FITs) achieve competence delivering telehealth care before entering the workforce. Feedback enhances telehealth skill development. This study develops a Rheumatology Telehealth Feedback Form (RTFF) that incorporates existing data and expertise as well as gathers validity evidence supporting its use.Methods: The American College of Rheumatology Workforce Solutions Committee formed a working group with expertise in rheumatic diseases, telehealth, and medical education. The working group conducted a modified Delphi and focus groups to define content grounded in Rheumatology Telehealth Competencies and evidence‐based practice as well as develop the RTFF. Rheumatology educators and FITs piloted the RTFF during patient care and simulated telehealth encounters, rating the helpfulness of the RTFF and providing data to calculate intraclass correlation coefficients (ICCs).Results: The modified Delphi identified 16 skills essential to conducting rheumatology telehealth encounters, which were converted into 17 items on the RTFF. Comment boxes prompted supplementary narrative. Five educators and 10 FITs piloted the materials. All educators (5 of 5) “agreed” or “strongly agreed” that the RTFF helped teach rheumatology telehealth skills. ICCs calculated from two simulated telehealth encounters demonstrated moderately to strongly supportive interrater reliability (ICC = 0.857 and 0.632, respectively).Conclusion: The RTFF incorporates an evidence‐based, expert consensus of the skills most essential for rheumatology telehealth encounters. Educators can use the RTFF as a guide for observing FITs delivering telehealth care, providing formative feedback, and helping FITs develop their skills before entering the workforce. The RTFF is the first direct observation formative assessment tool designed for teaching rheumatology telehealth skills. image
- Top Cited Papers
- 7 May 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (9) , 1115-1135
2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
Objective: The objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis.Methods: The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation.Results: We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response.Conclusion: This guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.
- 7 May 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (9) , 1115-1135
Top Cited Papers2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
Objective: The objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis.Methods: The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation.Results: We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response.Conclusion: This guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.
- Top Cited Papers
- 7 May 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (9) , 1045-1065
2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
Objective: The objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis.Methods: The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation.Results: We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response.Conclusion: This guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.
- 7 May 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (9) , 1045-1065
Top Cited Papers2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
Objective: The objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis.Methods: The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation.Results: We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response.Conclusion: This guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.
- 15 April 2025
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 32 (3) , 212-219
Healthcare utilization in a cohort receiving chronic disease specialty care by video telemedicine compared to propensity-matched adults not using telemedicine
Introduction: Telemedicine use has undergone rapid transformation in recent years. We designed this study to evaluate factors associated with telemedicine use and modality and the association with telemedicine use and healthcare utilization in a post-pandemic period. Methods: This observational study included four regions of the Alaska Tribal Health System. We used electronic health record data to evaluate a cohort of adults who had chronic disease specialty care visits, with or without telemedicine, between July 1, 2021 to December 31, 2021 for factors associated with telemedicine use and modality. We then evaluated the association between telemedicine use and healthcare utilization in 2022. We used propensity score matching to improve covariate balance between adults who had used telemedicine or not, and then estimated the effect of telemedicine on outcomes (inpatient hospitalizations, outpatient visits, and emergency department visits) using multivariable models. Results: Adults who used telemedicine were slightly older, had more chronic conditions and clinic visits, and resided in different regions compared to those who did not, with differences also observed between telemedicine modalities. The incident rate ratio for inpatient visits (1.16, p = 0.28), outpatient visits (1.15, p = 0.13), and emergency department visits (1.12, p = 0.36) were higher but not statistically significant for adults using telemedicine when compared to individuals not using telemedicine. Discussion: We found a non-significant association of higher rates of inpatient, outpatient, and emergency department visits in people who used telemedicine compared to propensity-matched “controls.” These findings should be considered in context of potential benefits of telemedicine and patient preference.
- 15 April 2025
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 32 (3) , 212-219
Healthcare utilization in a cohort receiving chronic disease specialty care by video telemedicine compared to propensity-matched adults not using telemedicine
Introduction: Telemedicine use has undergone rapid transformation in recent years. We designed this study to evaluate factors associated with telemedicine use and modality and the association with telemedicine use and healthcare utilization in a post-pandemic period. Methods: This observational study included four regions of the Alaska Tribal Health System. We used electronic health record data to evaluate a cohort of adults who had chronic disease specialty care visits, with or without telemedicine, between July 1, 2021 to December 31, 2021 for factors associated with telemedicine use and modality. We then evaluated the association between telemedicine use and healthcare utilization in 2022. We used propensity score matching to improve covariate balance between adults who had used telemedicine or not, and then estimated the effect of telemedicine on outcomes (inpatient hospitalizations, outpatient visits, and emergency department visits) using multivariable models. Results: Adults who used telemedicine were slightly older, had more chronic conditions and clinic visits, and resided in different regions compared to those who did not, with differences also observed between telemedicine modalities. The incident rate ratio for inpatient visits (1.16, p = 0.28), outpatient visits (1.15, p = 0.13), and emergency department visits (1.12, p = 0.36) were higher but not statistically significant for adults using telemedicine when compared to individuals not using telemedicine. Discussion: We found a non-significant association of higher rates of inpatient, outpatient, and emergency department visits in people who used telemedicine compared to propensity-matched “controls.” These findings should be considered in context of potential benefits of telemedicine and patient preference.
- 5 March 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (7) , 873-880
Prevalence and Clinical Characteristics of Vasculitis in the Alaska Native and American Indian Peoples of Alaska
Objective: Our objective was to determine the prevalence and clinical characteristics of vasculitis in Alaska Native and American Indian (AN/AI) peoples of Alaska.Methods: We queried the electronic health records of participating tribal health organizations within the Alaska Tribal Health System (ATHS) to identify adults with diagnostic codes related to vasculitis. Medical record abstraction was performed for all adults with potential vasculitis to confirm fulfillment of inclusion criteria, subtype, and clinical characteristics. The denominator for prevalence was the 2019 ATHS user population ≥ 18 (except giant cell arteritis [GCA], defined for persons ≥ 50).Results: The age‐adjusted prevalence per 1,000,000 AN/AI adults was 752 (95% confidence interval [CI] 581–959) for all vasculitis, with systemic vasculitis being the most common at 518 (95% CI 379–695). The most prevalent types of systemic vasculitis were antineutrophil cytoplasmic antibody–associated vasculitis (AAV) at 340 per million adults (95% CI 230–488) and GCA at 28 per 100,000 ≥ 50 (95% CI 12–56). The most prevalent subtype of AAV was granulomatosis with polyangiitis (GPA) at 244 per million adults (95% CI 148–380). AAV was diagnosed at a mean age of 54.2 years (SD 17), often with high markers of inflammation and renal involvement. GCA was diagnosed at a mean age of 69.6 years (SD 9.2).Conclusion: The prevalence of AAV (especially GPA) in AN/AI peoples is high. GCA prevalence is lower than White populations, but higher than many other populations. AN/AI peoples with AAV and GCA may present at younger ages with more severe disease than other populations.
- 5 March 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (7) , 873-880
Prevalence and Clinical Characteristics of Vasculitis in the Alaska Native and American Indian Peoples of Alaska
Objective: Our objective was to determine the prevalence and clinical characteristics of vasculitis in Alaska Native and American Indian (AN/AI) peoples of Alaska.Methods: We queried the electronic health records of participating tribal health organizations within the Alaska Tribal Health System (ATHS) to identify adults with diagnostic codes related to vasculitis. Medical record abstraction was performed for all adults with potential vasculitis to confirm fulfillment of inclusion criteria, subtype, and clinical characteristics. The denominator for prevalence was the 2019 ATHS user population ≥ 18 (except giant cell arteritis [GCA], defined for persons ≥ 50).Results: The age‐adjusted prevalence per 1,000,000 AN/AI adults was 752 (95% confidence interval [CI] 581–959) for all vasculitis, with systemic vasculitis being the most common at 518 (95% CI 379–695). The most prevalent types of systemic vasculitis were antineutrophil cytoplasmic antibody–associated vasculitis (AAV) at 340 per million adults (95% CI 230–488) and GCA at 28 per 100,000 ≥ 50 (95% CI 12–56). The most prevalent subtype of AAV was granulomatosis with polyangiitis (GPA) at 244 per million adults (95% CI 148–380). AAV was diagnosed at a mean age of 54.2 years (SD 17), often with high markers of inflammation and renal involvement. GCA was diagnosed at a mean age of 69.6 years (SD 9.2).Conclusion: The prevalence of AAV (especially GPA) in AN/AI peoples is high. GCA prevalence is lower than White populations, but higher than many other populations. AN/AI peoples with AAV and GCA may present at younger ages with more severe disease than other populations.